Leaders in Pharmaceutical Business Intelligence (LPBI) Group

⁦@pfizer⁩ #BIO2018 ⁦@AVIVA1950⁩ ⁦@Pharma_BI⁩ in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement #AI text mining sensation reported by patients with sensors #disease trajectory monitored drug device external partnership

⁦@Pfizer⁩ #BIO2018 ⁦@AVIVA1950⁩ ⁦@Pharma_BI⁩ #amyloid #cardiomyopathy new drug: Biotech in Scripps, CA and another in Cambridge, MA and ⁦@Pfizer⁩ as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma

⁦@Pfizer⁩ #BIO2018 ⁦@AVIVA1950⁩ ⁦@Pharma_BI⁩ #FDA and Medical community decide on directions for surrogate followed by survival NASH redefine NEW #endpoints drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration

⁦@pfizer⁩ immunicity correlated #vaccines confirm benefit in #registry based study #industry #consortium patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient #molecularbiology

⁦@Pfizer⁩ #BIO2018 ⁦@AVIVA1950⁩ ⁦@Pharma_BI⁩ redefine #medicine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection

⁦@pfizer⁩ #CEO Mikael Dolsten #BIO2018 ⁦@AVIVA1950⁩ @pharma_BI R&D budget for #neuroscience #oncology #venture contribution capital allocation focus on deep expertise in #translational multiple drugs in multiple indications Lipitor dependence ends patent expiration

#BIO2018 @Pharma_BI @AVIVA1950 #CS #Genomics only by knowing both one can develop applications in #Medicine #tools #analytics vs #AI #killer questions are the hard part vs #tools #domain expertise needed for structural models type of data collected #AI may not be best @atulbutte

#BIO2018 @AVIVA1950 @Pharma_BI #knowledge #gap

#BIO2018 @Pharma_BI @AVIVA1950 @atulbutte #PrecisionMedicine #drugdiscovery for idiopathic fibrosis using #AI CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug

#PrecisionMedicine for patients goals apply right approach to care right drug #BIO2018 @Pharma_BI @AVIVA1950 respond to therapy is a HC goal combined with patient goals

#BIO2018 @Pharma_BI @AVIVA1950 @FoundationMedicine in 7 days genomic data, clinical data and patient #characterization of patient took place #AI in #imaging #longitudinal #ML clean data sets are a must #algorithm for patient total clinical profile

#BIO2018 @Pharma_BI @AVIVA1950 #SELECT COHORT is assisted by #AI for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for #validation #sharing #data can get wrong results by using #shared #data

#BIO2018 @pharma_BI @AVIVA1950 #EMR @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials. @Regeneron use of #AI on genomic data for #patienttargeting

#BIO2018 #pharma_BI @AVIVA1950 @streamline #Bcorp #patients-based #social value #time in leadership is brief #move the dime #conviction

#BIO2018 #pharma_BI #@AVIVA1950 #LifeSciences #Industry #Leader to launch an industry #scienceleaders #taxincentives #legislation stick initiative #job #growth #strategy #metrowest